Application of 188rhenium as an alternative radionuclide for treatment of prostate cancer after tumor-specific sodium iodide symporter gene expression

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 11, 2007, Pages 4451-4458

  Willhauck, Michael J ^a   Samani, Bibi Rana Sharif ^a   Gildehaus, Franz Josef ^a   Wolf, Ingo ^b   Senekowitsch Schmidtke, Reingard ^b   Stark, Hans Jürgen ^c   Göke, Burkhard ^a   Morris, John C ^d   Spitzweg, Christine ^a,e  

^a UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d Mayo Clinic College of Medicine   (United States)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; PROSTATE SPECIFIC ANTIGEN; RHENIUM 188; SODIUM IODIDE SYMPORTER; COTRANSPORTER; RADIOACTIVE IODINE; RADIOISOTOPE; RHENIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG HALF LIFE; ELECTRON; GENE EXPRESSION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SCINTILLATION CAMERA; TUMOR XENOGRAFT; ADULT; ANIMAL; CANCER TRANSPLANTATION; CELL SURVIVAL; DRUG SCREENING; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETICS; HALF LIFE TIME; HUMAN; METABOLISM; NUDE MOUSE; PROSTATE TUMOR; TUMOR CELL LINE;

MUS MUSCULUS;

ADULT; ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE EXPRESSION REGULATION, NEOPLASTIC; HALF-LIFE; HUMANS; IODINE RADIOISOTOPES; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOISOTOPES; RHENIUM; SYMPORTERS; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 35348882187     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-0402     Document Type: Article

References (35)

1. Stearns ME, McGarvey T 1992 Prostate cancer: therapeutic, diagnostic, and basic studies. Lab Invest 67:540-552
2. Carroll PR, Chan JM, D'Amico AV, Gelmann EP, Iversen P, Klotz L, Nelson JB, Nelson PS, Nelson WG, Oh WK, Rosen N, Rubin MA, Sandler H, Sellers WR, Smith MR, Xu J, McMann MC, Kantoff PW 2004 Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment. J Urol 172(5 Pt 2):S3-S5
3. Dai G, Levy O, Carrasco N 1996 Cloning and characterization of the thyroid iodide transporter. Nature 379:458-460
4. Smanik PA, Liu Q, Furminger TL, Ryu K, Xing S, Mazzaferri EL, Jhiang SM 1996 Cloning of the human sodium iodide symporter. Biochem Biophys Res Commun 226:339-345
5. Spitzweg C, Morris JC 2002 The sodium iodide symporter: its pathophysiological and therapeutic implications. Clin Endocrinol (Oxf) 57:559-574
6. Spitzweg C, O'Connor MK, Bergert ER, Tindall DJ, Young CYF, Morris JC 2000 Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res 60:6526-6530
7. Spitzweg C, Zhang S, Bergert ER, Castro MR, McIver BD, Heufelder AE, Tindall DJ, Young CYF, Morris JC 1999 Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res 59:2136-2141
8. Kakinuma H, Bergert ER, Spitzweg C, Cheville JC, Lieber MM, Morris JC 2003 Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer. Cancer Res 63:7840-7844
9. Spitzweg C, Scholz IV, Bergert ER, Tindall DJ, Young CYF, Göke B, Morris JC 2003 Retinoic acid-induced stimulation of sodium iodide symporter expression and cytotoxicity of radioiodine in prostate cancer cells. Endocrinology 144:3423-3432
10. Scholz IV, Cengic N, Göke B, Morris JC, Spitzweg C 2004 Dexamethasone enhances the cytotoxic effect of radioiodine therapy in prostate cancer cells expressing the sodium iodide symporter. J Clin Endocrinol Metab 89:1108-1116
11. Spitzweg C, Dietz AB, O'Connor MK, Bergert ER, Tindall DJ, Young CYF, Morris JC 2001 In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther 8:1524-1531
12. Dwyer RM, Schatz SM, Bergert ER, Myers RM, Harvey ME, Classic KL, Blanco MC, Frisk CS, Marler RJ, Davis BJ, O'Connor MK, Russell SJ, Morris JC 2005 A preclinical large animal model of adenovirus-mediated expression of the sodium-iodide symporter for radioiodide imaging and therapy of locally recurrent prostate cancer. Mol Ther 5:835-841
13. Dohan O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M, Ginter CS, Carrasco N 2003 The sodium/Iodide symporter (NIS): characterization, regulation, and medical significance. Endocr Rev 24:48-77
14. Van Sande J, Massart C, Beauwens R, Schoutens A, Costagliola S, Dumont JE, Wolff J 2003 Anion selectivity by the sodium iodide symporter. Endocrinology 144:247-252
15. Dadachova E, Bouzahzah B, Zuckier LS, Pestell RG 2002 Rhenium-188 as an alternative to iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS). Nucl Med Biol 29:13-18
16. Lambert B, de Klerk JM 2006 Clinical applications of 188Re-labelled radiopharmaceuticals for radionuclide therapy. Nucl Med Commun 27:223-229
17. Dadachova E, Nguyen A, Lin EY, Gnatovskiy L, Lu P, Pollard JW 2005 Treatment with rhenium-188-perrhenate and iodine-131 of NIS-expressing mammary cancer in a mouse model remarkably inhibited tumor growth. Nucl Med Biol 32:695-700
18. Hoher M, Wohrle J, Wohlfrom M, Hanke H, Voisard R, Osterhues HH, Kochs M, Reske SN, Hombach V, Kotzerke J 2000 Intracoronary β-irradiation with a liquid (188)re-filled balloon: six-month results from a clinical safety and feasibility study. Circulation 101:2355-2360
19. Hoher M, Wohrle J, Wohlfrom M, Kamenz J, Nusser T, Grebe OC, Hanke H, Kochs M, Reske SN, Hombach V, Kotzerke J 2003 Intracoronary β-irradiation with a rhenium-188-filled balloon catheter: a randomized trial in patients with de novo and restenotic lesions. Circulation 107:3022-3027
20. Bunjes D, Buchmann I, Duncker C, Seitz U, Kotzerke J, Wiesneth M, Dohr D, Stefanic M, Buck A, Harsdorf SV, Glatting G, Grimminger W, Karakas T, Munzert G, Dohner H, Bergmann L, Reske SN 2001 Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. Blood 98:565-572
21. Knapp Jr FF 1998 Rhenium-188-a generator-derived radioisotope for cancer therapy. Cancer Biother Radiopharm 13:337-349
22. Murray A, Simms MS, Scholfield DP, Vincent RM, Denton G, Bishop MC, Price MR, Perkins AC 2001 Production and characterization of 188Re-C595 antibody for radioimmunotherapy of transitional cell bladder cancer. J Nucl Med 42:726-732
23. Seitz U, Neumaier B, Glatting G, Kotzerke J, Bunjes D, Reske SN 1999 Preparation and evaluation of the rhenium-188-labelled anti-NCA antigen monoclonal antibody BW 250/183 for radioimmunotherapy of leukaemia. Eur J Nucl Med 26:1265-1273
24. Weiss SJ, Philp NJ, Grollman EF 1984 Iodide transport in a continuous line of cultured cells from rat thyroid. Endocrinology 114:1090-1098
25. Mandell RB, Mandell LZ, Link CJ 1999 Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res 59:661-668
26. Stabin MG, Sparks RB, Crowe E 2005 OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 46:1023-1027
27. Scholz IV, Cengic N, Baker CH, Harrington KJ, Maletz K, Bergert ER, Vile R, Göke B, Morris JC, Spitzweg C 2005 Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer. Gene Ther 12:272-280
28. Cengic N, Baker CH, Schütz M, Göke B, Morris JC, Spitzweg C 2005 A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression. J Clin Endocrinol Metab 90:4457-4464
29. Dingli D, Bergert ER, Bajzer Z, O'Connor MK, Russell SJ, Morris JC 2004 Dynamic iodide trapping by tumor cells expressing the thyroidal sodium iodide symporter. Biochem Biophys Res Commun 325:157-166
30. Haberkorn U, Kinscherf R, Kissel M, Kübler W, Mahmut M, Sieger S, Eisenhut M, Peschke P, Altmann A 2003 Enhanced iodide transport after transfer of the human sodium iodide symporter gene is associated with lack of retention and low absorbed dose. Gene Ther 10:774-780
31. Sieger S, Jiang S, Schönsiegel F, Eskerski H, Kübler W, Altmann A, Haberkorn U 2003 Tumor-specific activation of the sodium/iodide symporter gene under control of the glucose transporter gene 1 promoter (GTI-1.3). Eur J Nucl Med Mol Imaging 30:748-756
32. Haberkorn U, Henze M, Altmann A, Jiang S, Morr I, Mahmut M, Peschke P, Kübler W, Debus J, Eisenhut M 2001 Transfer of the human NaI symporter gene enhances iodide uptake in hepatoma cells. J Nucl Med 42:317-325
33. Zuckier LS, Dohan O, Li Y, Chang CJ, Carrasco N, Dadachova E 2004 Kinetics of perrhenate uptake and comparative biodistribution of perrhenate, pertechnetate, and iodide by NaI symporter-expressing tissues in vivo. J Nucl Med 45:500-507
34. Kang JH, Chung JK, Lee YJ, Shin JH, Jeong JM, Lee DS, Lee MC 2004 Establishment of a human hepatocellular carcinoma cell line highly expressing sodium iodide symporter for radionuclide gene therapy. J Nucl Med 45:1571-1576
35. Shen DH, Marsee DK, Schaap J, Yang W, Cho JY, Hinkle G, Nagaraja HN, Kloos RT, Barth RF, Jhiang SM 2004 Effects of dose, intervention time, and radionuclide on sodium iodide symporter (NIS)-targeted radionuclide therapy. Gene Ther 11:161-169